Mirum Pharmaceuticals Stock - Analyst views and sector check at week’s end

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 19:47 CET. Details in the imprint.

Mirum Pharmaceuticals (US60471A1034) develops drugs for rare liver diseases and has seen its stock consolidate above the $100 mark on Nasdaq in recent sessions. Analyst coverage and sector comparisons highlight how this orphan-drug specialist is currently positioned among mid-cap biotechs.

What recent data show

Mirum Pharmaceuticals stock closed at $107.13 on Nasdaq on 06/18/2026, according to MarketBeat data, with extended-hours trading at $107.04 shortly after the close. MarketBeat’s quote page for Mirum reports a market capitalization in the mid single-digit billion-dollar range.

That level means Mirum currently trades in the upper bracket of US mid-cap biotech names focused on rare diseases, a segment where established orphan-drug franchises often command premium valuations compared with broader biotech indices.

Analyst coverage and consensus

Several Wall Street houses follow Mirum Pharmaceuticals shares, with MarketBeat reporting a consensus rating in the Buy range and an aggregate price target above the latest closing price. MarketBeat’s analyst research overview compiles recent upgrades, initiations and target changes for the stock.

The coverage reflects Mirum’s positioning as a commercial-stage rare-disease company with both approved therapies and an advancing pipeline, in contrast to many early-stage biotech peers that rely solely on trial milestones.

How Mirum compares in biotech

Within the US biotech universe, Mirum competes for capital with other liver-disease and rare-disease specialists, as well as a broader group of Nasdaq-listed biotechs with similar market caps. Sector investors typically compare launch execution, pricing durability and pipeline breadth.

Against this backdrop, Mirum’s combination of an existing revenue base from approved cholestatic liver-disease therapies, plus later-stage studies in adjacent indications, provides a clearer commercial profile than pure development-stage platforms of comparable size.

The product behind the stock

Mirum Pharmaceuticals generates revenue primarily from its prescription therapies for cholestatic liver diseases, led by maralixibat, a bile-acid transport inhibitor used in rare pediatric conditions. The company is also advancing additional indications and assets targeting similar pathways in hepatology.

Where the stock trades today

Mirum Pharmaceuticals shares trade on Nasdaq at $107.13 as of 06/18/2026, 16:00 Eastern, based on the latest available closing price.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.